Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2007

Côté Jean-François, Kirzin Sylvain, Kramar Andrew, Mosnier Jean-François, Diebold Marie-Danièle, Soubeyran Isabelle, Thirouard Anne-Sophie, Selves Janick, Laurent-Puig Pierre, Ychou Marc

Abstract excerpt

PURPOSE: Irinotecan (CPT-11) is approved in metastatic colorectal cancer treatment and can cause severe toxicity. The main purpose of our study was to assess the role of different polymorphisms on the occurrence of hematologic toxicities and disease-free survival in high-risk stage III colon cancer patients receiving 5-fluorouracil (5FU) and CPT-11 adjuvant chemotherapy regimen in a prospective randomized trial....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Disease-Free Survival

Share to Glucuronosyltransferase

Share to Irinotecan

Share to Pharmacogenetics

Share to Treatment Outcome

Source

Identifiers

PMID: 17510208
DOI: 10.1158/1078-0432.CCR-06-2290

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.PMID 17510208Read ↗

ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients.Semantic proximity Read ↗

UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.Semantic proximity Read ↗

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.Semantic proximity Read ↗

Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer：a study from Guangxi ZhuangSemantic proximity Read ↗

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.Semantic proximity Read ↗

UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.Semantic proximity Read ↗

Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer.Semantic proximity Read ↗

Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.Semantic proximity Read ↗

The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.Semantic proximity Read ↗

Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.